Trial · NCT07914270
Registered outcomes43
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 43
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Body Composition via Dual-Energy X-ray Absorptiometry (DXA) | Pre and post-intervention of 16 weeks | Whole body and segmental composition will be assessed through Dual-Energy X-ray Absorptiometry (DXA). Parameters analyzed will be: total and regional fat mass and lean mass and % of fat mass. |
| Primary | Change in handgrip strength | Pre and post-intervention of 16 weeks | Handgrip strength (Kg) will be assessed using hand-held dynamometry. Higher values indicate greater muscle strength |
| Primary | Change in lower limb Isokinetic muscle strength | Pre and post-intervention of 16 weeks | knee flexo-extension muscle strength will be assessed using an isokinetic dynamometer (Biodex®) at an angular velocity of 180°/s. Peak torque will be recorded in Newton-meters (Nm), with higher values indicating greater strength |
| Primary | Change in upper limb Isokinetic muscle Strength | Pre and post-intervention of 16 weeks | Elbow flexo-extension muscle strength will be assessed using an isokinetic dynamometer (Biodex®) at an angular velocity of 180°/s. Peak torque will be recorded in Newton-meters (Nm), with higher values indicating greater strength |
| Primary | Change in functional mobility and agility performance | Pre and post-intervention of 16 weeks | Functional mobility and agility will be assessed using the Timed Up and Go Test. The time required to stand from a chair, walk the standardized distance, turn, return, and sit down will be recorded in seconds. Lower values indicate better functional performance. |
| Primary | Change in lower body functional performance | Pre and post-intervention of 16 weeks | Lower-body functional capacity (resistance strength) will be assessed using the 30-Second Chair Stand Test. The number of complete sit-to-stand repetitions performed within 30 seconds will be recorded. Higher values indicate better functional performance. |
| Primary | Change in aerobic performance | Pre and post-intervention of 16 weeks | Functional aerobic capacity will be assessed using the 6-Minute Walk Test. The total distance walked during six minutes will be recorded in meters. Higher values indicate better functional capacity. |
| Secondary | Change in bone health (bone formation) | Pre and post-intervention of 16 weeks | Serum procollagen type I N-terminal propeptide (P1NP) will be measured as a marker of bone formation. |
| Secondary | Change in bone health (bone resorption) | Pre and post-intervention of 16 weeks | Serum C-terminal telopeptide of type I collagen (β-CTX) will be measured as a marker of bone resorption |
| Secondary | Change in cardiometabolic health (systolic blood pressure) | Pre and post-intervention of 16 weeks | Resting systolic blood pressure will be assessed and expressed in millimeters of mercury (mmHg), with lower values generally indicating lower cardiovascular risk. |
| Secondary | Change in cardiometabolic health (diastolic blood pressure) | Pre and post-intervention of 16 weeks | Resting diastolic blood pressure will be assessed and expressed in millimeters of mercury (mmHg), with lower values generally indicating lower cardiovascular risk. |
| Secondary | Change in metabolic biomarkers (total cholesterol) | Pre and post-intervention of 16 weeks | Total cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state. |
| Secondary | Change in metabolic biomarkers (HDL cholesterol) | Pre and post-intervention of 16 weeks | HDL cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state. |
| Secondary | Change in metabolic biomarkers (LDL cholesterol) | Pre and post-intervention of 16 weeks | LDL cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state. |
| Secondary | Change in metabolic biomarkers (Triglycerides) | Pre and post-intervention of 16 weeks | Triglycerides levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state. |
| Secondary | Change in metabolic biomarkers (fasting plasma glucose) | Pre and post-intervention of 16 weeks | Fasting plasma glucose concentration will be measured from blood samples collected after an overnight fasting period to assess changes in glucose homeostasis and metabolic state |
| Secondary | Change in metabolic biomarkers (GLP-1 Concentration) | Pre and post-intervention of 16 weeks | Circulating glucagon-like peptide-1 (GLP-1) concentration will be measured from blood samples to assess changes in this gut-derived metabolic hormone involved in glucose regulation |
| Secondary | Change in inflammation biomarkers (Interleukin-6 Concentration) | Pre and post-intervention of 16 weeks | Circulating interleukin-6 (IL-6) concentration will be measured from blood samples as a biomarker of systemic low-grade inflammation. |
| Secondary | Change in inflammation biomarkers (Tumor Necrosis Factor-Alpha Concentration) | Pre and post-intervention of 16 weeks | Circulating tumor necrosis factor-alpha (TNF-α) will be measured from blood samples as a biomarker of systemic low-grade inflammation. |
| Secondary | Change in Oxidative stress biomarkers (F2-Isoprostane Concentration) | Pre and post-intervention of 16 weeks | F2-isoprostanes will be measured from blood samples as biomarkers of oxidative stress and lipid peroxidation. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07914270/registered